Status:
UNKNOWN
Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease
Lead Sponsor:
VA Office of Research and Development
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50-90 years
Phase:
PHASE2
Brief Summary
Physical exercise has proven to improve memory including in the elderly. Drugs developed to stop the underlying disease processes that cause Alzheimer's disease may succeed only with multimodal effort...
Detailed Description
Subjects with Mild cognitive impairment (MCI) or Subjective Cognitive Impairment (SCD) are eligible for this study. MCI often represents the earliest stages of Alzheimer's disease (AD), as individuals...
Eligibility Criteria
Inclusion
- age between 50 and 90 years;
- Mini-Mental Status Exam (MMSE) scores greater than 24;
- subjective cognitive complaints based on subjective cognitive impairment questionaire (Gifford et al. 2015) including non-amnestic or amnestic cognitive deficits MCI (performance 1.5 standard deviation (SD) below normative means on The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) word list learning test);
- essentially intact activities of daily living (FAQ scores \< 6);
- Sedentary (exercise \< 30 minutes a day, 3 times a week);
- ambulatory, able exercise safely without cardiovascular symptoms, and able to pass a graded treadmill test modified for the elderly;
- able to arrange transportation to the study;
- Willing and intellectually able to understand and to sign an informed consent and to adhere to protocol requirements;
- community dwelling; and
- fluent in written and spoken English
- must screen positive for a Modified abbreviated MCI or SCD screen on phone, before coming in to clinic for extensive testing
Exclusion
- diagnosis of dementia,
- concurrent substance abuse disorder,
- psychosis or mood disorder,
- neurological disease affecting motor or cognitive abilities (e.g. Parkinson's disease),or other significant uncontrolled medical problems,
- cannot get up and down from floor
- initiation of any new medications/treatment for cognitive impairment (i.e. cholinesterase inhibitor, memantine) \< 6 months prior to study enrollment
Key Trial Info
Start Date :
January 20 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01811381
Start Date
January 20 2014
End Date
December 31 2020
Last Update
September 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States, 90073